Press release
Giant Cell Arteritis Market is expected to reach USD 3 billion by 2034
Giant Cell Arteritis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71357
Over the past decade, the GCA market has experienced remarkable growth, driven by advancements in biologic therapies, improved diagnostic techniques, and rising disease awareness. With the global elderly population expanding rapidly, the prevalence of GCA is expected to increase, propelling the market toward strong growth through 2034.
Market Overview
• Market Size (2024): USD 1.5 billion
• Forecast (2034): USD 3 billion
• CAGR (2025-2034): ~7.5%
• Key Growth Drivers: Aging population, approval of targeted biologics, improved imaging and diagnostic techniques.
• Key Challenges: High cost of biologics, underdiagnosis in emerging markets, long-term corticosteroid side effects.
• Leading Players: Roche (Genentech), Novartis AG, Sanofi, Bristol Myers Squibb, AbbVie, GSK, Janssen Pharmaceuticals.
The approval of tocilizumab (Actemra) by Roche marked a milestone in the treatment of GCA, moving care beyond corticosteroids. Other biologics and pipeline therapies are expected to transform treatment paradigms further, ensuring sustainable platelet count improvements and reduced relapse rates.
Segmentation Analysis
By Therapy Type
• Corticosteroids
• Biologics (e.g., Tocilizumab, Ustekinumab)
• Immunosuppressants (methotrexate, azathioprine)
• Others
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
By End Use
• Hospitals
• Specialty Clinics
• Research & Academic Institutes
• Homecare
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Summary: Corticosteroids remain the first-line therapy, but biologics such as tocilizumab are seeing rapid uptake, offering long-term remission and improved quality of life. Oral therapies are favored for initial treatment, while subcutaneous biologics dominate among advanced patients.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71357/giant-cell-arteritis-market
Regional Analysis
• North America: Largest market share due to high prevalence, strong healthcare infrastructure, and FDA approvals of biologics. The U.S. remains the dominant contributor.
• Europe: Strong adoption of advanced therapies supported by public healthcare reimbursement, with Germany, France, and the UK leading in market penetration.
• Asia-Pacific: Fastest-growing region, with rising elderly populations and improving diagnostic access. Japan and China represent major growth hubs.
• Middle East & Africa: Emerging market with limited diagnosis rates but improving access to treatments through government initiatives.
• Latin America: Brazil and Mexico are key contributors, gradually expanding adoption of biologics through healthcare investments.
Summary: North America and Europe currently dominate the GCA market, but Asia-Pacific is projected to post the fastest CAGR through 2034, driven by demographic shifts and improved healthcare infrastructure.
Market Dynamics
Key Growth Drivers
• Rising geriatric population, increasing GCA prevalence.
• Regulatory approvals and expanded access to biologic therapies.
• Enhanced imaging techniques (ultrasound, PET-CT, MRI) for early detection.
• Growing clinical trial pipeline targeting inflammation pathways.
Key Challenges
• High cost of biologics limiting access in emerging regions.
• Side effects of long-term corticosteroid use.
• Underdiagnosis due to symptom overlap with other conditions.
Latest Trends
• Expansion of biologics and monoclonal antibody therapies for long-term remission.
• Integration of AI-enabled imaging for faster diagnosis.
• Research into combination therapy (biologic + corticosteroid-sparing approaches).
• Focus on patient-centric care, including at-home biologic injections.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71357
Competitor Analysis
Major Players
• Roche (Genentech) - Leader with Actemra (tocilizumab), the first FDA-approved biologic for GCA.
• Novartis AG - Expanding research in immunology and inflammatory diseases.
• Sanofi - Strong biologic pipeline targeting rare autoimmune disorders.
• Bristol Myers Squibb - Active in immunosuppressive and biologic therapies.
• AbbVie - Advancing immunology-focused therapies.
• GSK - Building rare disease presence with inflammatory research.
• Janssen Pharmaceuticals (Johnson & Johnson) - Targeting autoimmune disorders through monoclonal antibody research.
Summary: The competitive landscape is consolidating around biologics, with Roche's Actemra setting the standard. However, competition is intensifying as Novartis, Sanofi, and AbbVie push new candidates into clinical development.
Conclusion
The giant cell arteritis market is undergoing a paradigm shift, moving from reliance on corticosteroids to biologic-driven treatment regimens. With robust pipeline activity, advanced diagnostics, and a growing elderly population, the market is set to expand significantly through 2034.
Key Takeaways:
• Biologics are driving growth, with tocilizumab setting a new benchmark.
• North America and Europe lead the market, but Asia-Pacific will see the fastest growth.
• High treatment costs remain a challenge, but expanding reimbursement and generic competition may improve access.
• The competitive race is focused on innovative biologics, diagnostics, and combination therapies.
The coming decade holds promise for earlier diagnosis, safer long-term treatments, and improved patient outcomes, positioning GCA as a high-potential market in autoimmune and inflammatory disease care.
This report is also available in the following languages : Japanese (巨細胞性動脈炎市場), Korean (거대세포 동맥염 시장), Chinese (巨细胞动脉炎市场), French (Marché de l'artérite à cellules géantes), German (Markt für Riesenzellarteriitis), and Italian (Mercato dell'arterite a cellule giganti), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71357/giant-cell-arteritis-market#request-a-sample
Our More Reports:
Community-Acquired Bacterial Pneumonia Market
https://exactitudeconsultancy.com/reports/71735/community-acquired-bacterial-pneumonia-market
Epidemic keratoconjunctivitis Market
https://exactitudeconsultancy.com/reports/71737/epidemic-keratoconjunctivitis-market
Helicobacter Pylori Infections Market
https://exactitudeconsultancy.com/reports/71739/helicobacter-pylori-infections-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Giant Cell Arteritis Market is expected to reach USD 3 billion by 2034 here
News-ID: 4165182 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for GCA
Giant Cell Arteritis Treatment Market Size, Share, Industry Growth 2032
Giant Cell Arteritis Treatment Market Overview
Giant Cell Arteritis (GCA) is a systemic vasculitis condition that causes inflammation of the blood vessels, primarily affecting the large arteries in the head, such as the temporal arteries. The global Giant Cell Arteritis Treatment Market is driven by rising healthcare expenditure and increased awareness of autoimmune diseases. Treatments focus on reducing inflammation, controlling symptoms, and preventing complications, primarily using corticosteroids and other immunosuppressive therapies.…
Property Consultancy Market Size in 2023 To 2029 | Savills, Deloitte NSE, Mott M …
The report also considers various economic conditions in key markets that have the potential to impact the market in the future. Taking into account all relevant factors, the report forecasts the market size of the Property Consultancy market. The report covers significant production statistics, including value, profitability, capacity, supply/demand ratio, volume, etc. Figures, pie charts, tables, and graphs display the most up-to-date information. These statistical representations provide predictive information about…
Global Giant cell arteritis (GCA) Market Analysis, Scope Significant Demand Mark …
From 2017 to 2028, the Infinity Business Insights report covers current treatment methods, developing medications, market share of various therapies, and the current and expected market size for Giant cell arteritis (GCA). Giant cell arteritis is a condition in which the lining of your arteries becomes inflamed. It usually affects your head's arteries, particularly those in your temples. As a result, giant cell arteritis is also known as temporal arteritis.…
Hand & arm protection Market 2021-2026| GCA Group, HONEYWELL INTERNATIONAL INC., …
The Global Hand & arm protection Market Report Organization's Researcher investigators specialists causes us to give our customers an exhaustive and top to bottom examination of market or industry alongside its key factors. The Market information introduced inside this report is acquired dependent on a few strategies, for example, PESTLE, Porter's Five, SWOT examination, the effect of Coronavirus/Coronavirus updates of Hand & arm protection, and others.
This report incorporates the assessment…
Breast Implants Market has Growing in Industry | GCA Group, Allergan , Silimed, …
The Global Breast Implants Market Report Organization's Researcher investigators specialists causes us to give our customers an exhaustive and top to bottom examination of market or industry alongside its key factors. The Market information introduced inside this report is acquired dependent on a few strategies, for example, PESTLE, Porter's Five, SWOT examination, the effect of Coronavirus/Coronavirus updates of Breast Implants, and others.
This report incorporates the assessment of Breast Implants market…
Global Breast Implants Market to Incur Rapid Extension During 2019 By Top Vendor …
The research study on Global Breast Implants Market organizes the overall perspective of the Breast Implants industry. This incorporates upcoming flow of the Breast Implants market together with an extensive analysis of recent industry statistics. It describes the Breast Implants market size as well as factors controlling market growth. Likewise, the report explains various challenges which affect Breast Implants market expansion. The report reviews economic prominence of the Breast Implants industry…
